> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# CareDx Lifts 2026 Profit Outlook To $90 Million-$100 Million After Revenue Jumps 39%
- URL: https://www.bullished.co/caredx-lifts-2026-profit-outlook-to-90-million-100-million-after-revenue-jumps-39-6537300b/
- Published: 2026-10-29T21:44:48.000Z
- Updated: 2026-10-29T21:44:48.000Z
- Description: The transplant-testing company also raised its 2026 revenue forecast to $520 million to $530 million on third-quarter sales of $139 million.
- Author: Matteo Parrino
- Tags: Earnings, CDNA, Industry: Healthcare

[CareDx](https://www.bullished.co/tag/cdna/), which sells blood tests that check transplant recipients for signs of organ injury or rejection, raised its 2026 outlook on Thursday after third-quarter [revenue jumped 39% to $139 million](https://www.sec.gov/Archives/edgar/data/0001217234/000121723426000059/cdna-20261029%5Fearningsrele.htm?ref=bullished.co). Adjusted EBITDA, the company's adjusted profit measure, is now expected at $90 million to $100 million for the year, up from $66 million to $78 million.

## Testing drives the quarter

Revenue was $139 million against $100 million a year earlier, driven mainly by Testing Services and Patient and Digital Solutions, the company said. Testing Services revenue rose 65% to $119 million, including $12 million from Specialty Oncology and $15 million for tests performed in prior periods, versus $6 million a year earlier.

Excluding that prior-period revenue, Testing Services grew approximately 58%. Volume was approximately 75,900 tests, up 51%, including contributions from Specialty Oncology. Patient and Digital Solutions revenue rose 31% to $20 million, led by CareDx Pharmacy services.

The quarter does not include Lab Products revenue, because CareDx completed the sale of that business on June 30, 2026.

## Profit climbs, helped by a tax benefit

Net income was $19 million, or [$0.35 per diluted share](https://wtop.com/national/2026/10/caredx-q3-earnings-snapshot/?ref=bullished.co), compared with $2 million, or $0.03 per share, a year earlier. An $8.6 million income tax benefit contributed to the result; income from operations was $8.1 million, against a small loss a year earlier.

Adjusted EBITDA reached $30 million, versus $15 million in the third quarter of 2025, a margin of about 22% against about 15%. CareDx attributed the gain to revenue growth, higher gross profit and disciplined spending. Operating cash flow was $13 million.

For the full year, revenue guidance rises to [$520 million to $530 million](https://wtop.com/national/2026/10/caredx-q3-earnings-snapshot/?ref=bullished.co) from $490 million to $500 million.

## Naveris deal and a bigger cash pile

CareDx closed its acquisition of Naveris on July 1, 2026, paying $160 million in cash with up to $100 million more in contingent consideration. That brought in the NavDx cancer test and the Specialty Oncology revenue.

Cash and cash equivalents stood at $250.5 million on September 30, up from $65.4 million at the end of 2025.

CEO John Hanna said the company sees "significant clinical interest in how molecular information can inform more decisions across a patient's care journey." CareDx is targeting a first-quarter 2027 commercial launch for AlloHeme and broader availability of HistoMap Kidney in 2027, with both aiming for lab-certification readiness before year-end.

CareDx is aiming for a first-quarter 2027 launch of AlloHeme, its next planned commercial product.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — CareDx, Inc. (CDNA)](https://www.sec.gov/Archives/edgar/data/0001217234/000121723426000059/cdna-20261029.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit cdna-20261029\_earningsrele.htm — CareDx, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001217234/000121723426000059/cdna-20261029%5Fearningsrele.htm?ref=bullished.co) — SEC EDGAR
- [CareDx: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/caredx-q3-earnings-snapshot-204228318.html?ref=bullished.co) — Associated Press
- [CareDx: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/caredx-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [CareDx: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/caredx-q3-earnings-snapshot/616-fd7153d1-7a89-47ff-86b8-648f875d795c?ref=bullished.co) — Associated Press
- [CareDx: Q3 Earnings Snapshot | king5.com](https://www.king5.com/article/syndication/associatedpress/caredx-q3-earnings-snapshot/616-fd7153d1-7a89-47ff-86b8-648f875d795c?ref=bullished.co) — Associated Press
- [CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus](https://finance.yahoo.com/healthcare/articles/caredx-report-q3-earnings-transplant-125800945.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance

### More on CareDx

- [CareDx's $19.3 Million Quarterly Profit Leans On An $8.6 Million Tax Benefit From The Naveris Deal](https://www.bullished.co/caredxs-19-3-million-quarterly-profit-leans-on-an-8-6-million-tax-benefit-from-the-naveris-ab5e09ca/)

[All CareDx (CDNA) coverage →](https://www.bullished.co/tag/cdna/)